Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Keytruda (pembrolizumab)
i
Other names:
MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(666)
News
Twitter
Trials
Company:
Merck (MSD)
Drug class:
PD1 inhibitor
Related drugs:
‹
nivolumab (546)
sintilimab (93)
toripalimab (81)
camrelizumab (77)
tislelizumab (67)
dostarlimab-gxly (33)
cemiplimab (28)
AB122 (16)
ABBV-181 (13)
PDR001 (13)
pucotenlimab (10)
AGEN2034 (9)
serplulimab (6)
retifanlimab-dlwr (6)
PF-06801591 (5)
MGD013 (5)
penpulimab (4)
nivolumab/relatlimab (4)
JNJ-63723283 (4)
cadonilimab (3)
PSB205 (3)
AK112 (3)
geptanolimab (2)
MEDI0680 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
MASCT-I (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
MEDI5752 (1)
XmAb717 (1)
609A (0)
AMP-224 (0)
AUNP-12 (0)
AWT020 (0)
AZD7789 (0)
BAT1306 (0)
BAT1308 (0)
(0)
BGB-108 (0)
BZD1901 (0)
BiCKI IL-7 (0)
CB213 (0)
CD200AR-L (0)
CDX-585 (0)
CMAB 819 (nivolumab biosimilar) (0)
EBV-specific anti-PD1 TCR-T cells (0)
enlonstobart (0)
prolgolimab (0)
GNR-051 (0)
HX-009 (0)
IAP0971 (0)
INCA32459 (0)
INCA33890 (0)
JS201 (0)
LB1410 (0)
LVGN3616 (0)
LZM009 (0)
MB12 (0)
MVR-C5252 (0)
MVR-T7011 (0)
NY-ESO-1 TCR-T cell therapy (0)
ONCR-177 (0)
OSE-279 (0)
nivolumab subcutaneous (0)
PD-1 knockout engineered T cells (0)
PD1 x TGFβR2 XmAb therapeutic (0)
PH-3861 (0)
PH-762 ACT (0)
PRGN-3007 (0)
QL1604 (0)
RB-340 (0)
SAR445877 (0)
SI-B003 (0)
SL-279252 (0)
SSGJ-705 (0)
SYN125 (0)
Sym021 (0)
T3011 (0)
TQB2868 (0)
TST005 (0)
TY 101 (0)
ZG005 (0)
YBL-006 (0)
anti PD-1 mAb (0)
anti-PD-1 antibody (0)
RG6279 (0)
MK-4280A (0)
IBI315 (0)
SCT-I10A (0)
XmAb23104 (0)
AMG 256 (0)
RG7769 (0)
MGD019 (0)
MK-3475 SC (0)
CT-011 (0)
BCD-217 (0)
MK-1308A (0)
IBI318 (0)
AZD2936 (0)
F520 (0)
RG6139 (0)
MK-7684A (0)
AMG 404 (0)
nivolumab (546)
sintilimab (93)
toripalimab (81)
camrelizumab (77)
tislelizumab (67)
dostarlimab-gxly (33)
cemiplimab (28)
AB122 (16)
ABBV-181 (13)
PDR001 (13)
pucotenlimab (10)
AGEN2034 (9)
serplulimab (6)
retifanlimab-dlwr (6)
PF-06801591 (5)
MGD013 (5)
penpulimab (4)
nivolumab/relatlimab (4)
JNJ-63723283 (4)
cadonilimab (3)
PSB205 (3)
AK112 (3)
geptanolimab (2)
MEDI0680 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
MASCT-I (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
MEDI5752 (1)
XmAb717 (1)
609A (0)
AMP-224 (0)
AUNP-12 (0)
AWT020 (0)
AZD7789 (0)
BAT1306 (0)
BAT1308 (0)
(0)
BGB-108 (0)
BZD1901 (0)
BiCKI IL-7 (0)
CB213 (0)
CD200AR-L (0)
CDX-585 (0)
CMAB 819 (nivolumab biosimilar) (0)
EBV-specific anti-PD1 TCR-T cells (0)
enlonstobart (0)
prolgolimab (0)
GNR-051 (0)
HX-009 (0)
IAP0971 (0)
INCA32459 (0)
INCA33890 (0)
JS201 (0)
LB1410 (0)
LVGN3616 (0)
LZM009 (0)
MB12 (0)
MVR-C5252 (0)
MVR-T7011 (0)
NY-ESO-1 TCR-T cell therapy (0)
ONCR-177 (0)
OSE-279 (0)
nivolumab subcutaneous (0)
PD-1 knockout engineered T cells (0)
PD1 x TGFβR2 XmAb therapeutic (0)
PH-3861 (0)
PH-762 ACT (0)
PRGN-3007 (0)
QL1604 (0)
RB-340 (0)
SAR445877 (0)
SI-B003 (0)
SL-279252 (0)
SSGJ-705 (0)
SYN125 (0)
Sym021 (0)
T3011 (0)
TQB2868 (0)
TST005 (0)
TY 101 (0)
ZG005 (0)
YBL-006 (0)
anti PD-1 mAb (0)
anti-PD-1 antibody (0)
RG6279 (0)
MK-4280A (0)
IBI315 (0)
SCT-I10A (0)
XmAb23104 (0)
AMG 256 (0)
RG7769 (0)
MGD019 (0)
MK-3475 SC (0)
CT-011 (0)
BCD-217 (0)
MK-1308A (0)
IBI318 (0)
AZD2936 (0)
F520 (0)
RG6139 (0)
MK-7684A (0)
AMG 404 (0)
›
Associations
(666)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
PD-L1 expression
Cervical Cancer
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive: A1 - Approval
ASCO 2023 - 3 days (New B)
pembrolizumab
Sensitive
:
A1
ASCO 2023 - 3d
pembrolizumab
Sensitive: A1 - Approval
ASCO 2023 - 3 days
pembrolizumab
Sensitive
:
A1
ASCO 2023 - 3 days - (New B)
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab + BCA101
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days (New C3)
pembrolizumab + BCA101
Sensitive
:
C3
ASCO 2023 - 3d
pembrolizumab + BCA101
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
pembrolizumab + BCA101
Sensitive
:
C3
ASCO 2023 - 3 days - (New C3)
RSPO3 fusion
Gastrointestinal Stromal Tumor
RSPO3 fusion
Gastrointestinal Stromal Tumor
pembrolizumab + CGX1321
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days (New C3)
pembrolizumab + CGX1321
Sensitive
:
C3
ASCO 2023 - 3d
pembrolizumab + CGX1321
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
pembrolizumab + CGX1321
Sensitive
:
C3
ASCO 2023 - 3 days - (New C3)
HLA-A*02:01 + PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
HLA-A*02:01 + PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab + CUE-101
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days (New C3)
pembrolizumab + CUE-101
Sensitive
:
C3
ASCO 2023 - 3d
pembrolizumab + CUE-101
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
pembrolizumab + CUE-101
Sensitive
:
C3
ASCO 2023 - 3 days - (New C3)
FGFR2-BICC1 fusion
Cholangiocarcinoma
FGFR2-BICC1 fusion
Cholangiocarcinoma
pembrolizumab + pemigatinib
Sensitive: C4 – Case Studies
Front Immunol - 4 days (New C4)
pembrolizumab + pemigatinib
Sensitive
:
C4
Front Immunol - 4d
pembrolizumab + pemigatinib
Sensitive: C4 – Case Studies
Front Immunol - 4 days
pembrolizumab + pemigatinib
Sensitive
:
C4
Front Immunol - 4 days - (New C4)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab + eftilagimod alpha
Sensitive: B - Late Trials
Immutep Limited Press Release - 1 week (New C3)
pembrolizumab + eftilagimod alpha
Sensitive
:
B
Immutep Limited Press Release - 1wk
pembrolizumab + eftilagimod alpha
Sensitive: B - Late Trials
Immutep Limited Press Release - 1 week
pembrolizumab + eftilagimod alpha
Sensitive
:
B
Immutep Limited Press Release - 1 week - (New C3)
MSI-H/dMMR
Thyroid Gland Papillary Carcinoma
MSI-H/dMMR
Thyroid Gland Papillary Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
pembrolizumab
Sensitive
:
A2
NCCN - 1wk
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 1 week
pembrolizumab
Sensitive
:
A2
NCCN - 1 week - (New A2)
PD-L1 overexpression
Triple Negative Breast Cancer
PD-L1 overexpression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks (New B)
pembrolizumab
Sensitive
:
B
ESMO-BC 2023 - 3wk
pembrolizumab
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks
pembrolizumab
Sensitive
:
B
ESMO-BC 2023 - 3 weeks - (New B)
MSI-H/dMMR
Colon Cancer
MSI-H/dMMR
Colon Cancer
pembrolizumab
Sensitive: A2 - Guideline
Int J Surg Case Rep - 3 weeks (New C4)
pembrolizumab
Sensitive
:
A2
Int J Surg Case Rep - 3wk
pembrolizumab
Sensitive: A2 - Guideline
Int J Surg Case Rep - 3 weeks
pembrolizumab
Sensitive
:
A2
Int J Surg Case Rep - 3 weeks - (New C4)
PD-L1 expression
Diffuse Large B Cell Lymphoma
PD-L1 expression
Diffuse Large B Cell Lymphoma
pembrolizumab + MVP-S
Sensitive: C3 – Early Trials
Eur J Haematol - 2 weeks (New C3)
pembrolizumab + MVP-S
Sensitive
:
C3
Eur J Haematol - 2wk
pembrolizumab + MVP-S
Sensitive: C3 – Early Trials
Eur J Haematol - 2 weeks
pembrolizumab + MVP-S
Sensitive
:
C3
Eur J Haematol - 2 weeks - (New C3)
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
pembrolizumab + MVP-S
Sensitive: C3 – Early Trials
Eur J Haematol - 2 weeks (New C3)
pembrolizumab + MVP-S
Sensitive
:
C3
Eur J Haematol - 2wk
pembrolizumab + MVP-S
Sensitive: C3 – Early Trials
Eur J Haematol - 2 weeks
pembrolizumab + MVP-S
Sensitive
:
C3
Eur J Haematol - 2 weeks - (New C3)
BRAF E501Q + PD-L1 negative
Lung Adenocarcinoma
BRAF E501Q + PD-L1 negative
Lung Adenocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
Respirol Case Rep - 3 weeks (New C4)
pembrolizumab
Sensitive
:
C4
Respirol Case Rep - 3wk
pembrolizumab
Sensitive: C4 – Case Studies
Respirol Case Rep - 3 weeks
pembrolizumab
Sensitive
:
C4
Respirol Case Rep - 3 weeks - (New C4)
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Solid Tumor
MSI-H/dMMR
Solid Tumor
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
No biomarker
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Cancer
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive: A1 - Approval
pembrolizumab + axitinib
Sensitive
:
A1
pembrolizumab + axitinib
Sensitive: A1 - Approval
pembrolizumab + axitinib
Sensitive
:
A1
No biomarker
Squamous Cell Skin Cancer
No biomarker
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Merkel Cell Carcinoma
No biomarker
Merkel Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
TMB-H
Solid Tumor
TMB-H
Solid Tumor
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK mutation
Non Small Cell Lung Cancer
ALK mutation
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Biliary Tract Cancer
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login